Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative serplulimab plus SOX versus placebo plus SOX for PD-L1-positive locally advanced gastric or esophagogastric junction adenocarcinoma
jRCT2031260297Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Jul 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of serplulimab, tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Henlius. Primary endpoint: Pathological complete response rate. Started Jul 2026; status: recruiting.
02
Drugs
serplulimabtegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031260297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260297.